Sector News

Turnaround-minded Teva CEO scouts deals in specialty generics, emerging markets

December 15, 2014
Life sciences
With a bounce-back in share price, Teva’s in a position to do something it hasn’t done much over the past few years: buy companies. And when it comes to getting back into the M&A game, CEO Erez Vigodman has a few types of targets at the top of his list.
 
On a quest to return to growth after a tumultuous 2013, Teva has its eye on complex generics manufacturers and emerging markets generics gurus, according to local newspaper Haaretz. Pickups in those fields should help Teva return to–and strengthen–its generic roots, a goal Vigodman has stressed during his first year in the helmsman’s seat.
 
And there’s room to do it. Take complex generics, for instance. High barriers to entry keep competition scarce–and, in some markets, it’s non-existent, Haaretz notes. Teva could move into specialty areas such as quick-dissolving thin films, patches and injectables, to name a few.
 
In some developing countries, Teva will need buyouts to get it up to speed. As the company’s global generics CEO, Sigurdur Olafsson, told Haaretz, it’s No. 81 in Brazil–an inappropriate position for a drugmaker of Teva’s size. The Petah Tikva-based pharma will be working to beef up its footprint in Mexico too, he said.
 
But that doesn’t mean Teva’s focusing exclusively on bolstering its generics business. Vigodman said he’s scouting for American companies that develop original drugs, which could help ease the branded sales decline nearing with the end of lead drug Copaxone’s patent life.
 
Teva has a share price revival to thank for putting it in a position to make some deals, Haaretz points out. Since Vigodman took up the reins early this year, the company’s stock has soared to $57 per share–a 40% increase–which gives it more firepower for equity-based buyouts.
 
But to preserve those gains, the company needs to keep the markets believing that profits lie beyond the Copaxone patent cliff. To that end, last Thursday the company said 2015 earnings would hit $5 to $5.30 per share, depending on when copycat challengers from teams of Mylan and India’s Natco Pharma and Novartis’ Sandoz and Momenta Pharmaceuticals hit the market.
 
By Carly Helfand
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).